{"groups":[{"description":"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (\"7 days on / 7 days off\" continuously)","id":"FG000","title":"Temozolomide"},{"description":"dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks","id":"FG001","title":"Dacarbazine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"22"}],"type":"Subject's Refusal unrelated to toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Death not due to malignancy/toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"22"}],"type":"Medical Decision unrelated toxicity/PD"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"13"}],"type":"Other Reason"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"12"}],"type":"Ongoing (still on treatment)"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Major Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"9"}],"type":"Toxicity (Related AE)"}],"milestones":[{"achievements":[{"comment":"10 subjects in temozolomide group not treated.","groupId":"FG000","numSubjects":"429"},{"comment":"9 subjects in dacarbazine group not treated.","groupId":"FG001","numSubjects":"430"}],"type":"STARTED"},{"achievements":[{"comment":"Progressive disease/relapse/death due to progressive disease","groupId":"FG000","numSubjects":"334"},{"comment":"Progressive disease/relapse/death due to progressive disease","groupId":"FG001","numSubjects":"348"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"95"},{"groupId":"FG001","numSubjects":"82"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}